WS #16664
Hedge funds have executed a massive $20 billion exit from US tech stocks over the past two weeks, the largest de-grossing since 2016, as the market braces for critical earnings from Apple and Palantir. The trend is evident in AMD's 10.88% slide and Palantir's drop of 6.27% despite a high P/E ratio, suggesting that investors are aggressively reducing exposure to high-multiple AI names ahead of potential guidance disappointments. This rotation away from growth signals a defensive posture that could pressure the broader Nasdaq if earnings fail to justify current valuations. In the AI and biotech sectors, Fresenius has tapped China's Wuxi Biologics to expand its biosimilar drug portfolio, highlighting the ongoing integration of AI-driven discovery with manufacturing. Meanwhile, Meta is reportedly collaborating with Shanghai-based Fourier Intelligence to develop a home-use humanoid robot prototype, marking a shift from pure software AI to physical embodiment. These developments signal continued investment in AI infrastructure and applications, though they are currently overshadowed by the broader market's focus on near-term earnings and macro de-risking.
Tech De-grossing and Earnings
Hedge funds have executed a massive $20 billion exit from US tech stocks over the past two weeks, the largest de-grossing since 2016, as the market braces for critical earnings from Apple and Palantir. The trend is evident in AMD's 10.88% slide and Palantir's drop of 6.27% despite a high P/E ratio, suggesting that investors are aggressively reducing exposure to high-multiple AI names ahead of potential guidance disappointments. This rotation away from growth signals a defensive posture that could pressure the broader Nasdaq if earnings fail to justify current valuations.
In the AI and biotech sectors, Fresenius has tapped China's Wuxi Biologics to expand its biosimilar drug portfolio, highlighting the ongoing integration of AI-driven discovery with manufacturing. Meanwhile, Meta is reportedly collaborating with Shanghai-based Fourier Intelligence to develop a home-use humanoid robot prototype, marking a shift from pure software AI to physical embodiment. These developments signal continued investment in AI infrastructure and applications, though they are currently overshadowed by the broader market's focus on near-term earnings and macro de-risking.